A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma
Primary Objective
Phase 1: To assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine. Phase 2: To assess preliminary efficacy as determined by overall response rate (ORR).
Details
Age
Adult
Type of Study
Treatment
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Brad Haverkos, MD
Study ID
Protocol Number: 22-1202
More information available at ClinicalTrials.gov: NCT05403450
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers